OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study
Wei‐Feng Qu, Zhen–Bin Ding, Xu-Dong Qu, et al.
BJS Open (2022) Vol. 6, Iss. 5
Open Access | Times Cited: 40
Wei‐Feng Qu, Zhen–Bin Ding, Xu-Dong Qu, et al.
BJS Open (2022) Vol. 6, Iss. 5
Open Access | Times Cited: 40
Showing 1-25 of 40 citing articles:
Hepatocellular carcinoma: signaling pathways and therapeutic advances
Jiaojiao Zheng, Siying Wang, Lei Xia, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 4
Jiaojiao Zheng, Siying Wang, Lei Xia, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 4
Conversion therapy for advanced hepatocellular carcinoma in the era of precision medicine: Current status, challenges and opportunities
Ming‐Da Wang, Xuejun Xu, Ke‐Chun Wang, et al.
Cancer Science (2024) Vol. 115, Iss. 7, pp. 2159-2169
Open Access | Times Cited: 10
Ming‐Da Wang, Xuejun Xu, Ke‐Chun Wang, et al.
Cancer Science (2024) Vol. 115, Iss. 7, pp. 2159-2169
Open Access | Times Cited: 10
Pretreatment CT-based machine learning radiomics model predicts response in unresectable hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors and interventional therapy
Yonglin Hua, Zhixian Sun, Yuxin Xiao, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 7, pp. e008953-e008953
Open Access | Times Cited: 10
Yonglin Hua, Zhixian Sun, Yuxin Xiao, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 7, pp. e008953-e008953
Open Access | Times Cited: 10
Efficacy and safety of transarterial chemoembolization combined with lenvatinib and PD-1 inhibitor in the treatment of advanced hepatocellular carcinoma: A meta-analysis
Lei Wang, Lin Li, Wei Zhou
Pharmacology & Therapeutics (2024) Vol. 257, pp. 108634-108634
Closed Access | Times Cited: 6
Lei Wang, Lin Li, Wei Zhou
Pharmacology & Therapeutics (2024) Vol. 257, pp. 108634-108634
Closed Access | Times Cited: 6
Outcomes and prognostic factors in initially unresectable hepatocellular carcinoma treated using conversion therapy with lenvatinib and TACE plus PD-1 inhibitors
Xingzhi Li, Jie Chen, Xiaobo Wang, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 15
Xingzhi Li, Jie Chen, Xiaobo Wang, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 15
TACE plus tyrosine kinase inhibitors and immune checkpoint inhibitors versus TACE plus tyrosine kinase inhibitors for the treatment of patients with hepatocellular carcinoma: a meta-analysis and trial sequential analysis
Jiaxi Liu, Peng Wang, Liqi Shang, et al.
Hepatology International (2023) Vol. 18, Iss. 2, pp. 595-609
Closed Access | Times Cited: 13
Jiaxi Liu, Peng Wang, Liqi Shang, et al.
Hepatology International (2023) Vol. 18, Iss. 2, pp. 595-609
Closed Access | Times Cited: 13
Outcomes of Salvage Surgery Versus Non-Salvage Surgery for Initially Unresectable Hepatocellular Carcinoma After Conversion Therapy with Transcatheter Arterial Chemoembolization Combined with Lenvatinib Plus Anti-PD-1 Antibody: A Multicenter Retrospective Study
Jiayi Wu, Jiayi Wu, Yang-Kai Fu, et al.
Annals of Surgical Oncology (2024) Vol. 31, Iss. 5, pp. 3073-3083
Closed Access | Times Cited: 5
Jiayi Wu, Jiayi Wu, Yang-Kai Fu, et al.
Annals of Surgical Oncology (2024) Vol. 31, Iss. 5, pp. 3073-3083
Closed Access | Times Cited: 5
Systemic Treatment for Unresectable Hepatocellular Carcinoma: A Surgeon’s Perspective
Xiao‐Dong Zhu, Lei Zhao, Binkui Li, et al.
Journal of Hepatocellular Carcinoma (2025) Vol. Volume 12, pp. 399-413
Open Access
Xiao‐Dong Zhu, Lei Zhao, Binkui Li, et al.
Journal of Hepatocellular Carcinoma (2025) Vol. Volume 12, pp. 399-413
Open Access
Immune checkpoint inhibitor plus tyrosine kinase inhibitor with or without transarterial chemoembolization for unresectable hepatocellular carcinoma
Hongyu Pan, Minghao Ruan, Riming Jin, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Hongyu Pan, Minghao Ruan, Riming Jin, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
PD-1 inhibitors improve the efficacy of tyrosine kinase inhibitors combined with transcatheter arterial chemoembolization in advanced hepatocellular carcinoma: a meta-analysis and trial sequential analysis
Jiahui Yu, Yong Li, Yuting Yang, et al.
Scandinavian Journal of Gastroenterology (2025), pp. 1-13
Closed Access
Jiahui Yu, Yong Li, Yuting Yang, et al.
Scandinavian Journal of Gastroenterology (2025), pp. 1-13
Closed Access
Real-world practice of conversion surgery for unresectable hepatocellular carcinoma - a single center data of 26 consecutive patients
Bo Zhang, Xuetao Shi, Kai Cui, et al.
BMC Cancer (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 12
Bo Zhang, Xuetao Shi, Kai Cui, et al.
BMC Cancer (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 12
Effect of transcatheter arterial chemoembolization combined with lenvatinib plus anti–PD-1 antibodies in patients with unresectable hepatocellular carcinoma: A treatment with Chinese characteristics
Jiayi Wu, Junyi Wu, Shuqun Li, et al.
BioScience Trends (2024) Vol. 18, Iss. 1, pp. 42-48
Open Access | Times Cited: 4
Jiayi Wu, Junyi Wu, Shuqun Li, et al.
BioScience Trends (2024) Vol. 18, Iss. 1, pp. 42-48
Open Access | Times Cited: 4
Resection post-radio-embolization in patients with single large hepatocellular carcinoma
Kevin Hakkakian, Nicolas Golse
HepatoBiliary Surgery and Nutrition (2024) Vol. 13, Iss. 2, pp. 307-310
Open Access | Times Cited: 4
Kevin Hakkakian, Nicolas Golse
HepatoBiliary Surgery and Nutrition (2024) Vol. 13, Iss. 2, pp. 307-310
Open Access | Times Cited: 4
Neoadjuvant therapy with triple therapy for Centrally located hepatocellular carcinoma
Wentao Bo, Luyao Zhang, Yan Chen, et al.
European Journal of Surgical Oncology (2025) Vol. 51, Iss. 5, pp. 109588-109588
Closed Access
Wentao Bo, Luyao Zhang, Yan Chen, et al.
European Journal of Surgical Oncology (2025) Vol. 51, Iss. 5, pp. 109588-109588
Closed Access
Neoadjuvant and Adjuvant Systemic Therapies in Loco-Regional Treatments for Hepatocellular Carcinoma: Are We at the Dawn of a New Era?
Riccardo Nevola, Augusto Delle Femine, Valerio Rosato, et al.
Cancers (2023) Vol. 15, Iss. 11, pp. 2950-2950
Open Access | Times Cited: 10
Riccardo Nevola, Augusto Delle Femine, Valerio Rosato, et al.
Cancers (2023) Vol. 15, Iss. 11, pp. 2950-2950
Open Access | Times Cited: 10
Application and Resistance Mechanisms of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma
Tao Meng, Jing Han, Juanyi Shi, et al.
Journal of Hepatocellular Carcinoma (2023) Vol. Volume 10, pp. 1069-1083
Open Access | Times Cited: 10
Tao Meng, Jing Han, Juanyi Shi, et al.
Journal of Hepatocellular Carcinoma (2023) Vol. Volume 10, pp. 1069-1083
Open Access | Times Cited: 10
Efficacy and safety analysis of TACE + Donafenib + Toripalimab versus TACE + Sorafenib in the treatment of unresectable hepatocellular carcinoma: a retrospective study
Haohao Lu, Bin Liang, Xiangwen Xia, et al.
BMC Cancer (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 10
Haohao Lu, Bin Liang, Xiangwen Xia, et al.
BMC Cancer (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 10
Comparison of survival benefit between salvage surgery after conversion therapy versus surgery alone for hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis
Yinbiao Cao, Haowen Tang, Bingyang Hu, et al.
HPB (2023) Vol. 25, Iss. 7, pp. 775-787
Closed Access | Times Cited: 9
Yinbiao Cao, Haowen Tang, Bingyang Hu, et al.
HPB (2023) Vol. 25, Iss. 7, pp. 775-787
Closed Access | Times Cited: 9
TACE combined Lenvatinib plus Camrelizumab versus TACE alone in efficacy and safety for unresectable hepatocellular carcinoma: a propensity score-matching study
Zhihong Tang, Tao Bai, Tao Wei, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 3
Zhihong Tang, Tao Bai, Tao Wei, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 3
Efficacy and safety of transarterial chemoembolization plus lenvatinib with or without programmed death-1 inhibitors in the treatment of unresectable hepatocellular carcinoma: a systematic review and meta-analysis
Junning Liu, Wei Song, Linfeng Yang, et al.
Journal of Cancer Research and Clinical Oncology (2023) Vol. 149, Iss. 15, pp. 14451-14461
Closed Access | Times Cited: 7
Junning Liu, Wei Song, Linfeng Yang, et al.
Journal of Cancer Research and Clinical Oncology (2023) Vol. 149, Iss. 15, pp. 14451-14461
Closed Access | Times Cited: 7
Proposal for Prognosis-Oriented Definition of Borderline Resectable Hepatocellular Carcinoma
Koichiro Haruki, Norifumi Harimoto, Kenei Furukawa, et al.
Journal of the American College of Surgeons (2024) Vol. 238, Iss. 6, pp. 1137-1147
Closed Access | Times Cited: 2
Koichiro Haruki, Norifumi Harimoto, Kenei Furukawa, et al.
Journal of the American College of Surgeons (2024) Vol. 238, Iss. 6, pp. 1137-1147
Closed Access | Times Cited: 2
Liver transplantation for advanced hepatocellular carcinoma after downstaging with consequential lenvatinib, transcatheter arterial chemoembolization and camrelizumab
Wei Peng, Youwei Wu, Xiaoyun Zhang, et al.
British journal of surgery (2024) Vol. 111, Iss. 3
Open Access | Times Cited: 2
Wei Peng, Youwei Wu, Xiaoyun Zhang, et al.
British journal of surgery (2024) Vol. 111, Iss. 3
Open Access | Times Cited: 2
Lenvatinib‑based treatment regimens in conversion therapy of unresectable hepatocellular carcinoma: A systematic review and meta‑analysis
Saixin Li, Zeyu Zhang, Zheng Wang, et al.
Oncology Letters (2024) Vol. 27, Iss. 6
Open Access | Times Cited: 2
Saixin Li, Zeyu Zhang, Zheng Wang, et al.
Oncology Letters (2024) Vol. 27, Iss. 6
Open Access | Times Cited: 2
Efficacy and safety of transarterial chemoembolization combined with targeted therapy and immunotherapy versus with targeted monotherapy in unresectable hepatocellular carcinoma: A systematic review and meta-analysis
Jingwen Feng, Yi Zhao, Lin Zhai, et al.
Medicine (2024) Vol. 103, Iss. 18, pp. e38037-e38037
Open Access | Times Cited: 2
Jingwen Feng, Yi Zhao, Lin Zhai, et al.
Medicine (2024) Vol. 103, Iss. 18, pp. e38037-e38037
Open Access | Times Cited: 2
Perioperative safety, oncologic outcome, and risk factors of salvage liver resection for initially unresectable hepatocellular carcinoma converted by transarterial chemoembolization plus tyrosine kinase inhibitor and anti-PD-1 antibody: a retrospective multicenter study of 83 patients
Kongying Lin, Zhi-Wen Lin, Qing-Jing Chen, et al.
Hepatology International (2023) Vol. 17, Iss. 6, pp. 1477-1489
Closed Access | Times Cited: 6
Kongying Lin, Zhi-Wen Lin, Qing-Jing Chen, et al.
Hepatology International (2023) Vol. 17, Iss. 6, pp. 1477-1489
Closed Access | Times Cited: 6
